Avery Wu Chairman
Executive vice president, Genuine C&C, Inc., Taiwan
Executive vice president, Taiwan Aries Co., Ltd., Taiwan
Sareina Wu, Ph.D. Founder / CEO
30+ years of R&D experience in Biomedical Sciences; non-viral gene therapy pioneer
Former President of Celgenomics, LLC USA
Former Faculty, Medical College of Georgia, USA; Former Assistant Research Professor, Chang Gung University
Ph.D., Vanderbilt University, USA
Dr. Sareina Wu is the Founder, CEO and Chief Scientific Officer of GenomeFrontier. Dr. Wu earned her PhD in Cell Biology at Vanderbilt University, USA and did her postdoctoral work at UC Santa Cruz. As a pioneer in developing a non-viral based genetic platform for human gene therapy, she founded Celgenomics, LLC in Georgia, USA. She also served as the Assistant Research Professor at Chang Gung University and was a junior faculty member at the Medical College of Georgia. Her works in the field of piggyBac are internationally recognized. She was invited to serve as a review committee for the research grant of Marsden Fund Council - Royal Society of New Zealand. Devoting nearly three decades in biomedical research, Dr. Wu has established substantial knowledge as well as research experiences in numerous fields of life sciences, stem cell and gene therapy.
Chien-Tsun Kuan, Ph.D. EVP/ COO and CTO
30+ years of R&D experience in Translational Sciences; antibody engineering & therapeutcs expert
Adjunct Associate Professor, Duke University Medical Center, USA; AACR Team Award, 2014
Former Deputy Executive Director, Institute of Biologics, Development Center for Biotechnology, Taiwan
Ph.D., Purdue University, USA; Fogarty Fellow, NIH, USA
Chien-Tsun Kuan, Ph.D.,
Dr. Kuan is EVP/COO & CTO of GenomeFrontier Therapeutics, a discovery to clinical stage company developing non-viral based CAR-T/ TCR-T cell therapies for the treatment of cancer, focusing on solid tumors. In this role he is responsible for guiding the research and development of the company’s pipeline assets as well as the business operation. Prior to his current position, Dr. Kuan was Deputy Executive Director of Institute of Biologics at Development Center for Biotechnology in Taipei, Taiwan, where he lead research and development of therapeutic antibodies, protein fusions, and cellular gene therapy for the treatment of cancer, autoimmune, neurodegenerative and infectious diseases. Earlier, Dr. Kuan was a faculty member at Duke University Medical Center, leading the Antibody Engineering and Antibody Therapeutics Program in the Preston Robert Tisch Brain Tumor Center at Duke to translate the laboratory results to clinical trials in cancer patients.
Dr. Kuan is an immunologist and molecular biologist with more than 25 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. degree in Biological Sciences from Purdue University and received postdoctoral training with Dr. Ira Pastan at the NIH in USA. He holds more than 25 U.S. or international patents, and is a recipient of numerous awards including the 2014 AACR Team Science Award, and an author of more than 45 peer-reviewed published research articles and numerous scientific presentations at national or international conferences in the areas of monoclonal antibodies, recombinant immunotoxins, bispecific antibodies, and CAR-T cell therapy for cancer treatment.
Karen Wen, Ph.D. Chief strategy & Product development Officer
30+ years of R&D experience in drug , biological, PIC/S GMP and GDP, IVD development, ISO system, monoclonal antibody development and business development; drug development expert
President of Mycenax Biotech Inc., 2011-2018; Vice President and Manager, Department of Quality Assurance of Mycenax Biotech Inc., 2001-2011
Research Fellow of Development Center for Biotechnology, and head of research and development of ISO plant for IVD, 1993-2000
Ph.D., Department of Biomedicine, Old Dominion University and Eastern Virginia Medical School, USA
Karen Wen is a pioneer in the field of process development and PIC/S GMP production of biological product including peptide, proteins, monoclonal antibodies, DNA vaccine and antibody-cell conjugate product. She, the co-founder and CEO of Mycenax Biotech Inc., the first CDMO in Taiwan, has profound experience in CMC (chemistry, manufacturing and control). In her term, she completed one product launched, one biosimilar in a global trial of bioequivalence in pharmacokinetics, several pipelines in the pre-IND stage. Besides of the pipeline development, Karen set up the GMP system of the facility and lead this facility as the first one to adopt single use technology in Asia and the first 2000L, the largest, disposable bioreactor in the world. She also led Mycenax to collaborate with Biosana to pursue the development of full-line continuous manufacturing which was the first one getting into the clinical phase.
Karen held the Ph.D in Biomedical Science of Old Dominion Univ./Eastern Virginia Medical School in US and B.S. in chemistry of National Taiwan University. She served as the principle investigator and researcher in the Division of Immunology and IVD Product Development in Development Center of Biotechnology. In her term, she successfully developed and commercialized the ELISA kits in drug residue determination (sulfa drugs, chloramphenicol, beta-agonist) for veterinary and dairy use, and ELISA and rapid tests for abuse drug residue determination (methamphetamine, morphine, cocaine, marijuana, FM2).
Karen is specialized in product development, GMP system set- up, CMC, product strategy, business development and company strategy.